Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2006

View Archived Issues

MK-0518 combination therapy yields HIV RNA reduction at 24 weeks

Novel antiarthritic compounds described in recent patents

Trimeris and Roche report on new potent fusion inhibitors with potential for once-weekly dosing

Insulin-stimulating properties of Hon-Chi reported

Targeting the pronociceptive action of CCK-8 for diabetes-induced peripheral sensitization

Novel treatment strategies for respiratory disorders claimed in recent patents

Ono patent discloses new compounds for treating HIV infection

ADA and EASD issue consensus statement on metformin treatment

Preliminary analysis from MEDAL program for Arcoxia

NeuroSearch to acquire Carlsson Research

CK-1827452 studied for oral administration

VivaGel studied for safety in men

Zileuton i.v. improves FEV1 in asthma patients

TPM-02/Insulin successfully delivers insulin across skin

Epigenetic targeting in psychopharmacology - a new avenue of research

KC-706 set to advance into phase II for inflammatory conditions

MGCD-0103 studied in phase II trial for relapsed or refractory Hodgkin's disease

NuPathe licenses LAD long acting delivery technology from U. of Pennsylvania

Dendreon submits sections of rolling BLA for Provenge

BrainStorm Cell Therapeutics to target stroke with adult stem cell technology

PXD-101 studied in aggressive B-cell lymphoma

GSK and ChemoCentryx establish strategic alliance in inflammatory disorders

Guanfacine extended release NDA filed for ADHD

ImmunoVaccine Technologies to use PADRE for vaccines

GlaxoSmithKline's Relenza approved in 15 E.U. countries

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...